Skip to main content
92% of eligible patients from the 12-week pivotal studies rolled over to the open-label, long-term extension study (LTE)*3
Study design of PSOARING 3, an open-label, long-term extension study of VTAMA® cream
Study design of PSOARING 3, an open-label, long-term extension study of VTAMA® cream
*90.1% on VTAMA cream, 86.4% on vehicle from PSOARING 1; 91.6% on VTAMA cream, 99.3% on vehicle from PSOARING 2.7,8
Patients electing not to participate in the LTE had a follow-up visit 4 weeks after completion of their treatment period.7,8
CONTINUED EFFICACY WHILE ON TREATMENT AND LASTING effect EVEN WHEN OFF-TREATMENT IN THE OPEN-LABEL, LONG-TERM EXTENSION STUDY (LTE)1,3
Grayed out human icon 21
DURABLE RESULTS FOR UP TO 52 WEEKS

No evidence of tachyphylaxis

six of ten (60%) of human icons highlighted purple
58% OF PATIENTS ACHIEVED PGA=0 OR 1

Of the patients (N=519) entering the LTE with PGA≥2, 58.2% achieved PGA=0 or 1 at least once during the 40-week, open-label LTE study3

VTAMA® icon within a refresh icon
~4 MONTHS OFF-TREATMENT EFFECT

Defined as median time to first worsening (PGA≥2) seen in patients (n=73) after 12 weeks of VTAMA cream treatment and entering the open-label LTE study with PGA=01

Calendar with 4 months inscription
Calendar with 4 months inscription
Clearer skin even if your patients are off-treatment
VTAMA cream has a ~4 month, off-treatment effect that is sustained for a median of approximately 4 months

73 patients who achieved complete disease clearance (PGA=0) after 12 weeks of VTAMA cream treatment entered the open-label, long-term extension (LTE) study and stopped treatment.1

Patients off-treatment maintained a PGA score of 0 or 1 for a median of 114 days (95% CI: 85 to 142 days) without disease worsening (defined as PGA≥2 [mild])1,3

Back to top